Loading...
Although most patients with Hodgkin lymphoma are cured by first-line therapy, those with primary treatment resistance or later relapse historically have poor outcomes. Now, investigators report the long-term follow-up of patients with relapsed or refractory Hodgkin lymphoma treated with the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) plus the anti-PD-1 monoclonal antibody nivolumab (Nivo), administered sequentially or in combination.
This phase 1–2 U.S. multicenter, industry-funded trial excluded patients with prior second-line radiation therapy, chemo/immunotherapy, or allogeneic or autologous stem cell transplantation (ASCT); patients with prior BV exposure were excluded in one cohort, whereas in another cohort, prior exposu…